NasdaqGM:XENE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.

Rewards

Loading...

Risk Analysis

Loading...

Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Xenon Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.9%

XENE

1.1%

US Biotechs

1.3%

US Market


1 Year Return

31.0%

XENE

29.0%

US Biotechs

6.1%

US Market


Shareholder returns

XENEIndustryMarket
7 Day3.9%1.1%1.3%
30 Day9.9%7.3%-0.3%
90 Day3.5%24.8%16.6%
1 Year31.0%31.0%30.3%29.0%8.4%6.1%
3 Year291.5%291.5%33.0%28.6%35.8%26.9%
5 Year16.0%16.0%-5.2%-10.6%62.7%44.7%

Price Volatility Vs. Market

How volatile is Xenon Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xenon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.58x

Price to Book (PB) ratio


Share Price vs. Fair Value


Price To Earnings Ratio


Price to Earnings Growth Ratio


Price to Book Ratio


Next Steps

Future Growth

How is Xenon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-18.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts


Earnings per Share Growth Forecasts


Future Return on Equity


Next Steps

Past Performance

How has Xenon Pharmaceuticals performed over the past 5 years?

-32.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis


Return on Equity


Next Steps

Financial Health

How is Xenon Pharmaceuticals's financial position?


Financial Position Analysis


Debt to Equity History and Analysis


Balance Sheet


Next Steps

Dividend

What is Xenon Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market


Stability and Growth of Payments


Current Payout to Shareholders


Future Payout to Shareholders


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Simon Pimstone (52yo)

17.5yrs

Tenure

US$2,612,720

Compensation

Dr. Simon N. Pimstone, M.B. ChB., Ph.D., FRCPC, M.D, is a Scientific Co-Founder of Xenon Pharmaceuticals Inc. in 1996 and has been its Chief Executive Officer since January 2003. He had served as President ...


CEO Compensation Analysis


Leadership Team

NamePositionTenureCompensationOwnership
Simon Pimstone
CEO & Director17.5yrsUS$2.61m0.78% $3.6m
Ian Mortimer
President2.33yrsUS$1.55m1.11% $5.2m
Ernesto Aycardi-Fonseca
Chief Medical Officer2.33yrsUS$1.07m0.13% $590.6k
Jodi Regts
Vice President of Corporate Affairs & Investor Relations3.33yrsno datano data
Shelley McCloskey
Senior Vice President of Human Resources0.83yrno datano data
Robin Sherrington
Executive Vice President of Strategy & Innovationno dataUS$552.84k0.048% $223.5k
James Empfield
Senior Vice President of Drug Discovery4.42yrsUS$545.00kno data

2.8yrs

Average Tenure

58yo

Average Age


Board Members

NamePositionTenureCompensationOwnership
Simon Pimstone
CEO & Director17.5yrsUS$2.61m0.78% $3.6m
Mohammad Azab
Independent Director16.75yrsUS$142.11k0.17% $807.2k
Frank Holler
Independent Director 21.33yrsUS$147.38k0.35% $1.6m
Michael Tarnow
Independent Chairman21.17yrsUS$169.62k0.20% $927.9k
Michael Hayden
Independent Director23.67yrsUS$131.93k0.78% $3.6m
Gary Patou
Independent Director16.5yrsUS$144.74k0.097% $452.8k
Clarissa Desjardins
Independent Director0.50yrno datano data
Steven Gannon
Independent Director5.17yrsUS$139.84k0.043% $199.7k
Dawn Svoronos
Independent Director3.83yrsUS$136.08k0.34% $1.6m

16.8yrs

Average Tenure

63yo

Average Age


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume


Recent Insider Transactions

Ownership Breakdown


Top Shareholders

Company Information

Xenon Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xenon Pharmaceuticals Inc.
  • Ticker: XENE
  • Exchange: NasdaqGM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$465.506m
  • Shares outstanding: 34.97m
  • Website: https://www.xenon-pharma.com

Number of Employees


Location

  • Xenon Pharmaceuticals Inc.
  • 200 – 3650 Gilmore Way
  • Burnaby
  • British Columbia
  • V5G 4W8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XENENasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDNov 2014
XP0DB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2014

Biography

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company’s product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/10 00:02
End of Day Share Price2020/07/09 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.